Calithera Biosciences, Inc
CALA
CALA was delisted on the 1st of February, 2023.
112 hedge funds and large institutions have $204M invested in Calithera Biosciences, Inc in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 38 increasing their positions, 23 reducing their positions, and 15 closing their positions.
140% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 15
65% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 23
23% more funds holding
Funds holding: 91 → 112 (+21)
10% less call options, than puts
Call options by funds: $768K | Put options by funds: $855K
50% less capital invested
Capital invested by funds: $406M → $204M (-$202M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$12.3M |
| 2 |
BlackRock
New York
|
+$10M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$6.69M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.11M |
| 5 |
Renaissance Technologies
New York
|
+$3.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$24.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$13.1M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$12.6M |
| 5 |
ACM
Atika Capital Management
New York
|
-$3.69M |
CALA Hedge Fund Activity: Q4 2017 in Review
112 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q4 2017, worth a combined $204M — down 50% from $406M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CALA positions and 15 closed out — a net gain of 21 holders — while 38 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $12.3M. The largest seller was Adage Capital Partners, cutting an estimated $24.9M.
- 112 institutional investors held Calithera Biosciences, Inc (CALA) as of Q4 2017, up from 91 in Q3 2017.
- Funds reported $204M of Calithera Biosciences, Inc stock for Q4 2017, down 50% quarter-over-quarter.
- 36 funds opened new Calithera Biosciences, Inc positions in Q4 2017 and 15 closed out, a net change of +21 holders.
- The largest Calithera Biosciences, Inc buyer in Q4 2017 was Millennium Management, an estimated $12.3M added.
- The largest Calithera Biosciences, Inc seller in Q4 2017 was Adage Capital Partners, an estimated $24.9M sold.
Based on aggregated 13F filings for Q4 2017.